EBioMedicine · 2020 · 29 citations · 34 references
MedicineOncologySurgeryGynecologic OncologyMetastasisSurgical OncologyCancer BiomarkersCytoreductive SurgeryMolecular Imaging In OncologyOvarian CancerTumor ImagingTumor MarkersCell Line-derived Xenograft ModelsFluorescence-guided SurgeryOrthotopic Tumor ModelsOvarian Cancer BiomarkersOvarian Cancer CytoreductionOvarian Cancer MetastasisOvarian Cytoreductive SurgeryOvarian Peritoneal Metastases
BACKGROUND: The completeness of resection is a key prognostic indicator in patients with ovarian cancer, and the application of tumour-targeted fluorescence image-guided surgery (FIGS) has led to improved detection of peritoneal metastases during cytoreductive surgery. CD24 is highly expressed in ovarian cancer and has been shown to be a suitable biomarker for tumour-targeted imaging. METHODS: CD24 expression was investigated in cell lines and heterogenous patient-derived xenograft (PDX) tumour samples of high-grade serous ovarian carcinoma (HGSOC). After conjugation of the monoclonal antibody CD24 to the NIR dye Alexa Fluor 750 and the evaluation of the optimal pharmacological parameters (OV-90, n = 21), orthotopic HGSOC metastatic xenografts (OV-90, n = 16) underwent cytoreductive surgery with real-time feedback. The impact of intraoperative CD24-targeted fluorescence guidance was compared to white light and palpation alone, and the recurrence of disease was monitored post-operatively (OV-90, n = 12). CD24-AF750 was further evaluated in four clinically annotated orthotopic PDX models of metastatic HGSOC, to validate the translational potential for intraoperative guidance. FINDINGS: CD24-targeted intraoperative NIR FIGS significantly (47•3%) improved tumour detection and resection, and reduced the post-operative tumour burden compared to standard white-light surgery in orthotopic HGSOC xenografts. CD24-AF750 allowed identification of minuscule tumour lesions which were undetectable with the naked eye in four HGSOC PDX. INTERPRETATION: CD24-targeted FIGS has translational potential as an aid to improve debulking surgery of ovarian cancer. FUNDING: This study was supported by the H2020 program MSCA-ITN [675743], Helse Vest RHF, and Helse Bergen HF [911809, 911852, 912171, 240222, 911974, HV1269], as well as by The Norwegian Cancer Society [182735], and The Research Council of Norway through its Centres of excellence funding scheme [223250, 262652].
34
Andreas du Bois, Eric Pujade‐Lauraine, Philipp Harter et al. · Cancer · 2009 · 1.6K citations · Full text
CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy
Amira Barkal, Rachel Brewer, Maxim Markovic et al. · Nature · 2019 · 1.4K citations
Life Sciences, Immunology, Oncology +14